In:
International Urology and Nephrology, Springer Science and Business Media LLC, Vol. 53, No. 12 ( 2021-12), p. 2493-2503
Abstract:
PD-L1 expression predicts response to immune checkpoint inhibitors in renal cell carcinomas (RCC), but has also been suggested to be linked to poor patient outcome. Methods We analyzed PD-L1 in 〉 1400 RCC in a tissue microarray format by immunohistochemistry. Results were compared with histological tumor type, parameters of cancer aggressiveness, and intratumoral CD8 + cytotoxic cells. Result At a cut-off level of 5% PD-L1 positive tumor cells, PD-L1 positivity was seen in 6.3% of 633 clear cell RCC (ccRCC), 18.2% of 165 papillary RCC, 18.8% of 64 chromophobe RCC, and 41.7% of 103 oncocytomas. In ccRCC, PD-L1 positivity was significantly linked to high ISUP ( p 〈 0.0001), Fuhrman ( p 〈 0.0001), Thoenes grade ( p 〈 0.0001), distant metastasis ( p = 0.0042), short recurrence-free ( p 〈 0.0001), and overall survival ( p = 0.0002). Intratumoral CD8 + lymphocytes were more frequent in PD-L1 positive (1055 ± 109) than in PD-L1 negative ccRCC (407 ± 28; p 〈 0.0001). PD-L positive immune cells were seen in 8.2% of all RCC and 13.9% of papillary RCC. In ccRCC, PD-L1 positive immune cells were linked to high numbers of tumor-infiltrating CD8 + cells ( p 〈 0.0001), high ISUP ( p 〈 0.0001), Fuhrman ( p = 0.0027), and Thoenes grade ( p 〈 0.0001), and poor tumor-specific survival ( p = 0.0280). Conclusions These data suggest that PD-L1 expression in highly immunogenic RCCs facilitates immune evasion and contributes to cancer aggressiveness.
Type of Medium:
Online Resource
ISSN:
0301-1623
,
1573-2584
DOI:
10.1007/s11255-021-02841-7
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2021
detail.hit.zdb_id:
2015547-5
Permalink